Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Cullinan Therapeutics (CGEM) Profit After Tax (2020 - 2023)

Cullinan Therapeutics (CGEM) has 4 years of Profit After Tax data on record, last reported at -$39.7 million in Q4 2023.

  • For Q4 2023, Profit After Tax fell 46.73% year-over-year to -$39.7 million; the TTM value through Dec 2023 reached -$169.0 million, down 258.41%, while the annual FY2025 figure was -$219.9 million, 31.21% down from the prior year.
  • Profit After Tax reached -$39.7 million in Q4 2023 per CGEM's latest filing, down from -$39.0 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $174.1 million in Q2 2022 and bottomed at -$58.1 million in Q1 2023.
  • Average Profit After Tax over 4 years is -$11.8 million, with a median of -$22.5 million recorded in 2021.
  • The widest YoY moves for Profit After Tax: up 1158.85% in 2022, down 1008.53% in 2022.
  • A 4-year view of Profit After Tax shows it stood at -$36.0 million in 2020, then increased by 4.38% to -$34.4 million in 2021, then grew by 21.44% to -$27.0 million in 2022, then tumbled by 46.73% to -$39.7 million in 2023.
  • Per Business Quant database, its latest 3 readings for Profit After Tax were -$39.7 million in Q4 2023, -$39.0 million in Q3 2023, and -$32.2 million in Q2 2023.